Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

This week in Other Barks & Bites: the USPTO terminates 52,000 trademark applications and registrations via sanctions; the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

The American Civil Liberties Union of Indiana filed the lawsuit in September 2024 against IU and Purdue University for policies incurred from SEA 202.

The judge determined the state's policies are protected by the 10th Amendment, a blow to Trump's efforts to crack down on sanctuary jurisdictions.

On Wednesday, July 16, a lawsuit was filed against the University of Colorado Colorado Springs, alleging that the university failed to protect its students in the aftermath of a deadly shooting tha… ...